RAPT
Income statement / Annual
Last year (2024), RAPT Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, RAPT Therapeutics, Inc.'s net income was -$129.87 M.
See RAPT Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$1.53 M |
$3.81 M |
$5.04 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$3.55 M
|
$2.81 M
|
$996,000.00
|
$0.00
|
$1.33 M
|
$1.24 M
|
$1.38 M
|
| Gross Profit |
$0.00
|
-$3.55 M
|
-$1.28 M
|
$2.82 M
|
$5.04 M
|
-$1.33 M
|
-$1.24 M
|
-$1.38 M
|
| Gross Profit Ratio |
0
|
0
|
-0.84
|
0.74
|
1
|
0
|
0
|
0
|
| Research and Development Expenses |
$107.22 M
|
$101.00 M
|
$67.08 M
|
$56.99 M
|
$45.49 M
|
$34.91 M
|
$31.77 M
|
$25.62 M
|
| General & Administrative Expenses |
$28.88 M
|
$26.06 M
|
$20.24 M
|
$16.04 M
|
$12.77 M
|
$8.72 M
|
$5.18 M
|
$3.71 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$28.88 M
|
$26.06 M
|
$20.24 M
|
$16.04 M
|
$12.77 M
|
$8.72 M
|
$5.18 M
|
$3.71 M
|
| Other Expenses |
$0.00
|
$0.00
|
$1.96 M
|
$5,000.00
|
$1.31 M
|
$1.29 M
|
$800,000.00
|
$216,000.00
|
| Operating Expenses |
$136.10 M
|
$127.06 M
|
$87.32 M
|
$73.02 M
|
$58.26 M
|
$43.63 M
|
$36.95 M
|
$29.33 M
|
| Cost And Expenses |
$0.00
|
$127.06 M
|
$87.32 M
|
$73.02 M
|
$58.26 M
|
$43.63 M
|
$36.95 M
|
$29.33 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$1.22 M
|
$2.81 M
|
$996,000.00
|
$1.12 M
|
$1.33 M
|
$1.24 M
|
$1.38 M
|
| EBITDA |
-$136.10 M |
-$125.85 M |
-$84.75 M |
-$68.21 M |
-$52.09 M |
-$42.30 M |
-$35.71 M |
-$27.95 M |
| EBITDA Ratio |
0
|
0
|
-56.19
|
-18.15
|
-10.55
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
-56.19
|
-18.15
|
-10.55
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$6.24 M
|
$10.26 M
|
$1.96 M
|
$5,000.00
|
$1.31 M
|
$1.29 M
|
$800,000.00
|
$216,000.00
|
| Income Before Tax |
-$129.87 M
|
-$116.80 M
|
-$83.84 M
|
-$69.20 M
|
-$51.90 M
|
-$42.34 M
|
-$36.15 M
|
-$29.12 M
|
| Income Before Tax Ratio |
0
|
0
|
-54.9
|
-18.15
|
-10.29
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$1.96 M
|
-$996,000.00
|
$990,000.00
|
$660,000.00
|
$800,000.00
|
$0.00
|
| Net Income |
-$129.87 M
|
-$116.80 M
|
-$81.88 M
|
-$68.21 M
|
-$52.89 M
|
-$43.00 M
|
-$36.15 M
|
-$29.12 M
|
| Net Income Ratio |
0
|
0
|
-53.62
|
-17.89
|
-10.49
|
0
|
0
|
0
|
| EPS |
-3.19 |
-3.05 |
-2.52 |
-2.49 |
-2.19 |
-1.97 |
-2.09 |
-2.01 |
| EPS Diluted |
-3.19 |
-3.05 |
-2.52 |
-2.49 |
-2.19 |
-1.97 |
-2.09 |
-2.01 |
| Weighted Average Shares Out |
$40.76 M
|
$38.34 M
|
$32.54 M
|
$27.39 M
|
$24.13 M
|
$21.83 M
|
$17.33 M
|
$14.46 M
|
| Weighted Average Shares Out Diluted |
$40.76 M
|
$38.34 M
|
$32.54 M
|
$27.39 M
|
$24.13 M
|
$21.83 M
|
$17.33 M
|
$14.46 M
|
| Link |
|
|
|
|
|
|
|
|
